GlassScriptPhysician profile
Naila Ahmad
NPI 1770641078
$18,685.76
in general payments reported to CMS, 2019-2025
53 companies · $2,615 in 2025
The $2,615 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,347 · 2020: $2,029 · 2021: $3,099 · 2022: $2,747 · 2023: $2,948 · 2024: $2,902 · 2025: $2,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,305 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,305.25 |
| Education | $158.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,151.15 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,769.35 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,692.30 | 2019-2025 | |
| Novo Nordisk INC | $1,265.94 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Vanda Pharmaceuticals INC. | $746.42 | 2020-2025 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $724.48 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $719.80 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $662.90 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $646.76 | 2020-2025 | Caplyta |
| Astellas Pharma US INC | $630.42 | 2019-2025 | Veozah, Myrbetriq |
| Lundbeck LLC | $603.90 | 2020-2025 | Rexulti |
| Amgen INC. | $415.12 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.70 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $393.62 | 2022-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $372.38 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naila Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.